[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642812":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":49,"collaborators":20,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":72,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Rutgers, The State University of New Jersey","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: MR-guided Adaptive Pelvic IMRT","EXPERIMENTAL","Participants receive moderately hypofractionated MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) delivered via MR-linac to a total dose of 42 Gy in 15 fractions with daily onboard MRI and online adaptive replanning as needed to optimize target coverage and minimize radiation exposure to surrounding organs at risk. Vaginal brachytherapy may be administered following IMRT at the treating physician's discretion per institutional standards.",[13],"Radiation: MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT)","Participants receive moderately hypofractionated MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) delivered via MR-linac to a total dose of 42 Gy in 15 fractions with daily onboard MRI guidance and online adaptive replanning as needed to optimize target coverage and minimize radiation exposure to surrounding organs at risk.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Lara M Hathout","Rutgers University - Cancer Institute","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Lara Hathout, MD","CONTACT","732-235-2465","Lh547@rutgers.edu",[33],{"facility":34,"status":20,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Rutgers Cancer Institut Jersey","New Brunswick","New Jersey","08901","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-74.45182,40.48622,{"lat":44,"lon":43},[47],{"name":48,"role":29,"phone":20,"phoneExt":20,"email":20},"Lara Hathout",{"type":25,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Lara Hathout, MD, FRCPC","Associate Professor, Rutgers Cancer Institute, Department of Radiation Oncology","100642812","adaptive-daily-mr-guided-adjuvant-pelvic-therapy-endometrial-cancer-100642812",false,"NCT07643012","Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer","Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer: A Phase I\u002FII Feasibility Study","ADAPT-EC","Inclusion Criteria:\n\n1. Histologically confirmed endometrial carcinoma (endometrioid, serous, clear cell, carcinosarcoma, or dedifferentiated histology).\n2. Indication for adjuvant pelvic radiotherapy (± vaginal brachytherapy) for HIR defined by the ASTRO guidelines and GOG-99(7, 9) :\n3. Age\n4. High-grade histology (grade 2-3)\n5. Depth of myometrial invasion\n6. LVSI\n7. Positive pelvic nodes\n8. Cervical stromal invasion\n9. Presence of poor prognostic molecular markers\n10. Age ≥18 years.\n11. Ability to provide informed consent.\n12. Eligible to receive adjuvant systemic therapy, if indicated, with a minimum 3-week interval between chemotherapy and radiotherapy.\n13. Willing and able to complete EORTC QLQ-C30 and EN-24 questionnaires in a validated language version.\n\nExclusion Criteria:\n\n1. Prior pelvic radiotherapy.\n2. Contraindication to pelvic radiotherapy (e.g., active connective tissue disorder or inflammatory bowel disease).\n3. Presence of a hip prosthesis that would compromise treatment planning or delivery.\n\n   \\-","FEMALE","18 Years","90 Years",{"count":64,"type":65},30,"ESTIMATED","INTERVENTIONAL",[68],"NA","To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.",[71],"Endometrial Cancer","NOT_YET_RECRUITING","2026-06-09",{"date":75,"type":76},"2026-06-11","ACTUAL",{"date":78,"type":65},"2026-06",{"date":80,"type":65},"2029-06",{"name":5,"class":6},1]